Reinforcing the supply chain of antiviral drugs with retrosynthetic software

The coronavirus pandemic of 2020 shook global supply chains and caused widespread economic disruptions that are still being felt today. The heightened need for novel therapies to treat COVID-19 reached critical status early on during the pandemic, and as a result, new technologies to speed drug development and reduce the risk of failure were being tried. One such approach was used by the Cernak research group at the University of Michigan where they used SYNTHIA™ Retrosynthesis Software to arrive at alternative synthetic routes for the known antiviral drug umifenovir, as well as eleven other antiviral and anti-inflammatory drugs. Read more about their strategy and approach to optimize the synthesis routes to these important drugs in their recent Nature Communications paper.